Response‐adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T‐cell therapy in relapsed/refractory large B‐cell lymphoma: A retrospective observational study

Response‐adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T‐cell therapy in relapsed/refractory large B‐cell lymphoma: A retrospective observational study

Abstract Background CD19 chimeric antigen receptor (CAR) T‐cell therapy is a potential treatment for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The combination of targeted therapeutic strategies, particularly bruton tyrosine kinase inhibitor zanubrutinib and programmed death‐1 inhibitor...

Full description

Saved in:
Bibliographic Details
Main Authors: Rong Shen, Wei‐Guo Cao, Li Wang, Ling‐Shuang Sheng, Yi‐Lun Zhang, Wen Wu, Peng‐Peng Xu, Shu Cheng, Meng‐Ke Liu, Yan Dong, Yue Wang, Xiang‐Qin Weng, Xu‐Feng Jiang, Qi Song, Hong‐Mei Yi, Lei Li, Sheng Chen, Zi‐Xun Yan, Wei‐Li Zhao
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Clinical and Translational Medicine
Subjects:
bruton tyrosine kinase inhibitor
chimeric antigen receptor T‐cell therapy
large B‐cell lymphoma
programmed death‐1 inhibitor
tumour microenvironment
Online Access:https://doi.org/10.1002/ctm2.70310
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/ctm2.70310

Similar Items